Show simple item record

dc.contributor.authorMas, Sergi
dc.contributor.authorJulià, Laura
dc.contributor.authorCuesta, Manuel J.
dc.contributor.authorCrespo Facorro, Benedicto
dc.contributor.authorVázquez Bourgon, Javier
dc.contributor.authorSpuch, Carlos
dc.contributor.authorGonzález-Pinto, Ana
dc.contributor.authorIbáñez, Angela
dc.contributor.authorUsall, Judith
dc.contributor.authorRomero López Alberca, Cristina 
dc.contributor.authorCatalan, Ana
dc.contributor.authorMané, Anna
dc.contributor.authorBernardo, Miquel
dc.contributor.otherPsicologíaes_ES
dc.date.accessioned2025-09-03T13:32:14Z
dc.date.available2025-09-03T13:32:14Z
dc.date.issued2024
dc.identifier.issn1664-0640
dc.identifier.urihttp://hdl.handle.net/10498/37032
dc.description.abstractThe application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of Applied Pharmacogenetics to Predict Response to Treatment of First Psychotic Episode (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected. These predictors will integrate, through machine learning techniques, pharmacogenetic (measured as polygenic risk scores) and epigenetic data together with clinical, sociodemographic, environmental, and neuroanatomical data. To do this, the FarmaPRED-PEP project will use data from two already recruited cohorts: the PEPS cohort from the “Genotype-Phenotype Interaction and Environment. Application to a Predictive Model in First Psychotic Episodes” study (the PEPs study from the Spanish abbreviation) (N=335) and the PAFIP cohort from “Clinical Program on Early Phases of Psychosis” (PAFIP from the Spanish abbreviation) (N = 350). These cohorts will be used to create the predictor, which will then be validated in a new cohort, the FarmaPRED cohort (N = 300). The FarmaPRED-PEP project has been designed to overcome several of the limitations identified in pharmacogenetic studies in psychiatry: (1) the sample size; (2) the phenotype heterogeneity and its definition; (3) the complexity of the phenotype and (4) the gender perspective. The global reach of the FarmaPRED-PEP project is to facilitate the effective deployment of precision medicine in national health systems.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media SAes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceFrontiers in Psychiatry - 2024, Vol. 15es_ES
dc.subjectantipsychotices_ES
dc.subjectpersonalized medicinees_ES
dc.subjectPharmacogeneticses_ES
dc.subjectpredictiones_ES
dc.subjectpsychosises_ES
dc.titleApplied pharmacogenetics to predict response to treatment of first psychotic episode: study protocoles_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3389/FPSYT.2024.1497565
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional